Alexandria Penwell
Mobile, ALNPI 1972180537
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 26.2% of the total.
Across 96 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$596
- UCB, Inc.$310
- SK Life Science, Inc.$273
- AbbVie$145
- Novartis$125
- Jazz Pharmaceuticals Inc.$116
- plus $712 from 16 others
What the payments were for
- Food & beverage$2,277100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 23 | $596 |
| UCB, Inc. | 15 | $310 |
| SK Life Science, Inc. | 9 | $273 |
| AbbVie | 7 | $145 |
| Novartis | 5 | $125 |
| Jazz Pharmaceuticals Inc. | 5 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $107 |
| Acadia Pharmaceuticals Inc | 5 | $104 |
| Tanabe Pharma America, Inc. | 6 | $100 |
| Acorda Therapeutics, Inc | 2 | $45 |
| Genentech USA, Inc. | 2 | $44 |
| EMD Serono, Inc. | 2 | $41 |
| Biogen | 2 | $37 |
| Merz Pharmaceuticals, LLC | 1 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Argenx US, Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $26 |
| MDD US Operations, LLC | 1 | $24 |
| Medline Industries LP | 1 | $23 |
| Neurelis, Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $19 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.